Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$SBFM: Sunshine Biopharma Discusses the Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast
Click here:
https://www.newsfilecorp.com/release/74719/Sunshine-Biopharma-Discusses-the-Progress-of-Its-COVID19-and-Anticancer-Compounds-with-The-Stock-Day-Podcast
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
#DDAmanda Chart (CLASSIC Insider Play) on: $FBCD :
You can find these before they run:
What the Fact (Factor) Column is:
The Factor is a proprietary indicator used for scanning in #DDAmanda.
It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).
SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.
That's significant, and many times indicates that a run in the stock is coming.
SPRWF .40 pot stock got excellent revenue report after hour.
Worth a look. Pot is hot.
DC wants to legalize it. That’s just a matter of time. SPRWF has a killer facility and doesn’t need the US to stay alive. The US is going to push this .40 stock above $4.00
After this stupid impeachment, DC has nothing to offer Anerica. Pot is going to be it to lift them from tgst embarrassing show of “Unity”.
I’m accumulating
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161759558
ORMTQ is the Cheapest CH11-CLEAN-Shell with the FIXED Sought-After Super Tiny SS! A ideal Reverse-Merger candidate or Custodianship-Taking-Over target...
Easy to shoot the Dime Land based on its peer's market value! Huge potential to hit the Dollar Land in the short term!
Its peer ALLMQ (the New symbol is "ALLM", 245,865,278/500M shares Large OS/AS) did run 36.4-Bagger from $0.0022 to $1.5 within only several months! To match the Same market value, ORMTQ (18,662,272/100M shares Small OS/AS) will create a New Record-High $19.7617 v.s. at 99.953% Giant discount price $0.0094 now!
TONR is on Big Fire today! Up 20% from the New bottom support 0.0005! Easy to break up its recent high 0.0025 again!
To match the Same market value with its Same-Bottom and Similar-SS peer PUGE (3.5B+/5B shares OS/AS) at 0.0060, TONR will create a New 52-week high 0.0308 which is 308 Times of its bottom price 0.0001!
So TONR is much much much cheaper than its peers PUGE and ALYI etc. now!
MDCE is up 25% so far! Extremely Oversold --- from 0.0007 to 0.0002!
Huge potential to run 11-Bagger Quick rally from current joke low price (0.0005)...
To match the Same market value with its peer CIVX at 0.0055, MDCE will create a New 52-week high 0.0055 which is 55 Times of its Bottom price 0.0001!
Note, both MDCE and CIVX have almost the Same OS counts.
So MDCE is much much much cheaper than AXXA and CIVX now!
$AXXA +10.17% good day all day, keep an eye on it
https://stockcharts.com/h-sc/ui?s=axxa
$SBFM Sunshine Biopharma Completes Application to Uplist to OTCQB
MONTREAL, QC / ACCESSWIRE / January 27, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed and submitted the application to uplist to the OTCQB. While the Company is currently a fully reporting issuer trading on OTC Markets PINK, management has determined that an uplist to OTCQB is aligned with the Company's overall growth trajectory as it will allow institutional investors to participate.
https://www.accesswire.com/users/newswire/images/626135/SUNSHINEBIO-LOGO111820.jpg
The OTCQB Venture Market, operated by OTC Markets Group Inc. in New York City, is a premier market for early stage and developing companies. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
Sunshine Biopharma's CFO, Camille Sebaaly, stated, "Joining the OTCQB is a pivotal milestone for the Company and elevates Sunshine's reputation among the investment community. We would like to thank our shareholders for their continued support as the Company has been steadily growing and making advancements in research and development."
About Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.4 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
http://www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
TONR is on Big Fire today! Up 100% from the New bottom 0.0003! Easy to hit 0.0014 again!
To match the Same market value with its Same-Bottom and Similar-SS peer PUGE (3.5B+/5B shares OS/AS) at 0.0060, TONR will create a New 52-week high 0.0309 which is 309 Times of its bottom price 0.0001!
So TONR is much much much cheaper than its peers BTIM and PUGE now!
FRCN was up 20% yesterday! Hyper Oversold --- from 0.0024 to 0.0001 within only a couple of weeks! Easy to hit 0.0010 in the coming week...
Both FRCN and its peer RITE have almost the Same Maximal trading volume (600M shares) in history and Similar 52-week-high --- 0.0024 vs 0.0020!
Both RITE and FRCN are much much much cheaper than SWRM now!
$SBFM is well funded to deliver its vitally needed Coronavirus Treatment.
Sunshine Biopharma Receives Fourth Tranche From Previously Announced $2,000,000 + Financing for Coronavirus Treatment
MONTREAL, QC / ACCESSWIRE / January 14, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.
https://www.accesswire.com/users/newswire/images/624274/SUNSHINEBIO-LOGO111820.jpg
Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, "As a company, we continue to forge forward in our development of a COVID treatment and our anticancer compounds. This investment capital has been integral to our progress in each of these sectors."
Brett Rosen and Deborah Braun of RB Capital Partners Inc. stated, "We are very impressed with the Sunshine leadership team and their commitment to developing critical life-saving medical treatments. Our investment money has been met with ongoing milestones and we are pleased to be considered a long-term funding partner of the Company. We are looking forward to a potential up-list to the Nasdaq in the future."
About Sunshine Biopharma's Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 1.9 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for several molecules which were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply. Sunshine Biopharma has since completed the synthesis of four such molecules and identified a lead compound, SBFM-PL4. In collaboration with the University of Georgia, College of Pharmacy, the Company is currently advancing the development of SBFM-PL4 through the in vitro testing stage to be followed by mice studies before entering clinical trials on COVID-19 patients.
About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
http://www.sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View source version on accesswire.com:
https://www.accesswire.com/624274/Sunshine-Biopharma-Receives-Fourth-Tranche-From-Previously-Announced-2000000-Financing-for-Coronavirus-Treatment
SWRM ready for next leg up chart screaming buy
FBCD is up 50% today with Huge Slapping volumes! Ready to soar back to the Penny Land again...
To match the Same market value with its peer CIVX (3B+/5B shares OS/AS) at 0.0055, FBCD will create a New 52-week high 0.0115 which is 115 Times of its Bottom price!
So FBCD is much much much cheaper than CIVX now!
In fact its recent high 0.013 = 43.33+ Time of its current ridiculous low price 0.0003!
RITE is up 50% today with the Largest Slapping volumes! The most recent high was 0.0020 several months ago! Today's high is 0.00044! It should be easy to test 52-week-high 0.0020 again since the FIXED SS is the Same and all its similar-SS peers exploded to similar levels nowadays...
RITE is much much much cheaper than GSFI now!
CRRSQ is at Hyper Oversold status --- from 0.0415 to 0.0007! It only has 16M shares FIXED Super Tiny float which is the Lowest among the majority of its CH11-"Q" peers!
Easy to hit Multiple Pennies again with only a couple of millions share's Slapping volumes...
To match the Same MV with its CH11-peer CBLAQ at 0.07, CRRSQ will create a New high 0.0871 which is 109.88%-Higher than its New 52-week high 0.0415! Note, 0.0871 = 27.22 Times of its current ridiculous low price 0.0032!
So CRRSQ is much much much cheaper than CBLAQ now!
$ALYI Rideshare market is over $50 billion and projected to reach $220 billion by 2025.
https://seekingalpha.com/instablog/21922151-bioresearch-alert/5354767-alyi-alternet-systems-turning-hemp-stronger-lighter-cars-and-powerful-batteries
$IDEX Ideanomics The Co Is In The Commercial Fleet Operator Space
$NGTF Enjoy Nightfood Tonight - Low Calorie, Great Tasting Ice Cream Formulated to Help Improve Sleep.
$GSFI released exciting news today! https://finance.yahoo.com/news/green-stream-holdings-prepares-ne-173600235.html
$ZAAG official website: https://www.eatatzen.com/, visit now
MDCE is up 50% so far! Extremely Oversold --- from 0.0007 to 0.0002! Huge potential to run 16-Bagger Quick rally from current joke low price (0.0003)...
To match the Same market value with its peer CIVX (2.5B+/5B shares Huge/Giant OS/AS) at 0.0055, MDCE will create a New 52-week high 0.0047 which is 47 Times of its Bottom price 0.0001!
So MDCE is much much much cheaper than QBIO and CIVX now!
LOCMQ is up 32.4% today! It will soon break out its current joke low 52-week-high 0.0199 based on meager 23M shares FIXED Super Tiny OS and 21M shares FIXED Super Tiny float!
At Hyper Oversold status --- from its Post-CH11-First-Bouncing-High 0.17 to its All-Time-Low 0.0001!
This CH11-CLEAN-shell is also Super Undervalued now --- mere $0.1M MV v.s. its CH7-peer (CERPQ) ever hit $7.5M MV most recently!
Easy 10-Bagger Quick rally from here (0.0050) to create Another New high 0.05 (i.e. $1.1M MV)...
To match the Same MV with CERPQ at 0.1, LOCMQ will hit 0.3203 which is 64.06 Times of its current price 0.0050!
RCMH is on Huge Fire today! It is currently the Cheapest 0.0001-Bottom OTC stock! This hidden gem has CLEAN shell status! Very High Insider's Ownership! Ready to be acquired through a Reverse-Merger deal or Custodianship-Taking-Over by David Lazar etc....
RCMH will Easily And Quickly surge back to its recent high 0.0018 again based on only 851M shares FIXED Low OS count and less than 500M shares Small float count...
To match the same market value with its peer VIBI (2,960,023,326 shares OS) at 0.0053, RCMH will create a New 52-week high 0.01843 which is 184.3 Times of its Bottom price 0.0001!
To match the Same market value with its peer CIVX (2.5B+/5B shares Huge/Giant OS/AS) at 0.0055, RCMH will create a New 52-week high 0.0165 which is 165 Times of its Bottom price!
To match the Same market value with its peer PUGE (3B+/2.99B shares OS/AS) at 0.0040, RCMH will create a New 52-week high 0.0141 which is 141 Times of its bottom price 0.0001!
So RCMH is much much much cheaper than QBIO, VIBI, CIVX, and PUGE now!
RCMH is up 14.3% today! It is currently the Cheapest 0.0001-Bottom OTC stock! At CLEAN shell status! Ready to be acquired through Reverse-Merger deal or Custodianship-Taking-Over by David Lazar etc....
RCMH will Easily And Quickly surge back to its recent high 0.0018 again based on only 851M shares FIXED Low OS count and less than 500M shares Small float count...
To match the same market value with its peer VIBI (2,960,023,326 shares OS) at 0.0053, RCMH will create a New 52-week high 0.01843 which is 184.3 Times of its Bottom price 0.0001!
To match the Same market value with its peer PUGE (3B+/2.99B shares OS/AS) at 0.0040, RCMH will create a New 52-week high 0.0141 which is 141 Times of its bottom price 0.0001!
To match the Same market value with its peer CIVX (2.5B+/5B shares Huge/Giant OS/AS) at 0.0055, RCMH will create a New 52-week high 0.0165 which is 165 Times of its Bottom price!
So RCMH is much much much cheaper than VIBI, PUGE, and CIVX!
LIQDQ is a High-Tech SOFTWARE company with Microsoft's huge interest in its advanced trading technologies, platform, and products!
This hidden gem is at Hyper Oversold status --- over 94.68% Huge price crash from its most recent high $0.0188 to its Bottom $0.0010!
LIQDQ has $0.06734 a share Huge Cash Liquidation Value --- see the screenshot from its bankruptcy court document below!
LIQDQ is Super Undervalued now --- its total Net Asset = 186.4 Times of its ridiculous low Market Value at its Bottom!
LIQDQ has Giant Positive Book Value --- $0.1864 a share from its latest 10-Q!
LIQDQ also has Giant Positive Cash Value --- ($0.2 a share from its latest 10-Q!
Its most recent high $0.0188 = 9.4 Times of its current ridiculous low price $0.0020!
The recent high was $0.045 v.s. LIQDQ is trading at 95.56% Huge discount price $0.0020 now!
Even its Negative Book Value (-$0.0762 a share) CH7-"Q" peer (RCPIQ) could Quickly run 20-Bagger to hit $1.01M Market Value just a few months ago! Buying RCPIQ at $0.0059 = buying LIQDQ at $0.0166 v.s. at joke low price $0.0020 now!
To match the Same MV with its CH7-"Q" peer CERPQ at $0.1, LIQDQ will create a Multi-Year's New high $0.123 which is 61.5 Times of its current 98.7% Giant discount price $0.0020!
So LIQDQ is much much much cheaper than CERPQ and RCPIQ now!
$BTIM is on LinkedIn, see profile: https://www.linkedin.com/company/boatim
#BTIM
$HRAL Price History https://www.barchart.com/stocks/quotes/HRAL/price-history/historical
FRCN is up over 33.33% today! Hyper Oversold --- from 0.0024 to 0.0001 within only a couple of weeks though FRCN is 100%-more expensive than RCMH now!
Buying FRCN at 0.0005 = buying RCMH at 0.0010!
FRCN has over 1.7B+/1.5B+ shares Huge OS/float v.s. RCMH only has 0.8B shares Low OS and less than 0.5B shares Small float!
DESTQ is up 11.43% today! This hidden gem is heading back onto 0.029 now...
Its most recent high was $0.029 v.s. it is trading at joke low $0.012 currently!
DESTQ is Super Undervalued now!
The Cash Value alone is over $0.1203 per share!
DESTQ is also Hyper Oversold --- 98.455% Giant price crash from the pre-CH11 Bottom $0.33 to the New Bottom $0.0051!
The current 52-week-high is $0.0344 now!
DESTQ has the FIXED Sought-After Super Tiny SS --- 9M/14M/20M shares float/OS/AS!
RCMH is much much much cheaper than MWXRF now!
$UMAX Share structure https://www.otcmarkets.com/stock/UMAX/security
On Radar! Market Makers great interest here! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$MWXRF Great for Mineworx! ... a potential standard to address two market sectors totaling $193 billion, ...
Mineworx Technologies and EnviroLeach Technologies https://mineworx.net/partnerships/
Mineworx and Enviroleach have entered into a Joint Venture for the processing of E-Waste materials in a facility located in Surrey, Canada and operates under the name Envirocircuit. The strategic relationship was created in an effort to capitalize on the assets and skill sets of both parties to develop an innovative, turn-key and environmentally friendly solution for E-Waste processing. Mineworx’s equity participation and ownership within the Joint Venture will be 20%.
$MWXRF Mineworx Corporate Update Webinar Now Available Online
November 26, 2020
On Tuesday, November 24th Greg Pendura, President and CEO of Mineworx Technologies (TSXV: MWX) provided investors with a detailed update and the framework for moving from pilot plant testing to initial commercialization.
Mineworx has independently developed technology and processes for the extraction of platinum and palladium from diesel catalytic converters.
Key highlights include the following:
Smelters are currently turning away diesel catalytic converters as they can create safety issues, because trapped carbon can ignite and cause an explosion, which can damage furnaces,
Third party engineering for pilot plant design is completed,
Pilot plant is fully funded and is expected to be operational in late Q1 2021,
David Recycling will supply the feedstock for the fully commercialized facility,
The company forecasts the start of phase one of full commercialization in late 2021,
Full scale production of its first plant is expected to generate over $100 million in revenue, with a gross margin of ~20%,
Business strategy is to build and operate multiple plants throughout North America.
$SGTM Decrease of authorized shares from 3,249,000,000 to 250,000,000, a 93% reduction, as of July 21
LOCMQ is up 50% today! It will soon break out its current joke low 52-week-high 0.0199 based on 23M shares FIXED Super Tiny OS and 21M shares FIXED Super Tiny float!
At Hyper Oversold status --- from the Post-CH11-First-Bouncing-High 0.17 to the All-Time-Low 0.0001!
LOCMQ is also Super Undervalued now --- mere $0.1M MV v.s. its CH7-peer (CERPQ) ever hit $7.5M MV!
Easy 10-Bagger Quick rally from here (0.0045) to hit Another New high 0.045 (i.e. $1M MV)...
To match the Same MV with CERPQ at 0.1, LOCMQ will hit 0.3203 which is 71.18 Times of its current price 0.0045!
CIVX (2.55B/5B shares OS/AS) is up 16.7% so far! Easy to hit last week's high 0.0011 again though it is much much more expensive than RCMH (0.8B/2B shares Low OS/AS)...
Followers
|
678
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
294602
|
Created
|
06/04/10
|
Type
|
Free
|
Moderator Value_Investor | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |